8-K
IDEXX LABORATORIES INC /DE (IDXX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 1, 2022
IDEXX LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-19271 | 01-0393723 |
|---|---|---|
| (State or other jurisdiction<br><br><br>of incorporation) | (Commission<br><br><br>File Number) | (IRS Employer<br><br><br>Identification No.) |
| One IDEXX Drive, Westbrook, Maine | 04092 | |
| --- | --- | |
| (Address of principal executive offices) | (ZIP Code) |
- 556.0300
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br><br>Symbol(s) | Name of each exchange<br><br><br>on which registered |
|---|---|---|
| Common Stock, $0.10 par value per share | IDXX | NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 1, 2022, IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with general instructions to Form 8-K, the information in this Form 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.
| Exhibit No. | Description of Exhibit |
|---|---|
| 99.1 | Press Release entitled “IDEXX Laboratories Announces Third Quarter Results,” issued by the Company on November 1, 2022. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IDEXX LABORATORIES, INC. | ||
|---|---|---|
| Date: November 1, 2022 | By: | /s/ Brian P. McKeon |
| Brian P. McKeon | ||
| Executive Vice President,<br><br><br>Chief Financial Officer and Treasurer |
Exhibit 99.1
IDEXX Laboratories Announces Third Quarter Results
- Achieves third quarter revenue growth of 4% reported and 8% organic, driven by CAG Diagnostics recurring revenue growth of 5% reported and 9% organic, building on high prior year growth
- Continued strong demand for diagnostic services and excellent commercial execution support record third quarter premium instrument placements, driving 14% growth in global premium instrument installed base
- Delivers EPS of $2.15, an increase of 6% as reported and 13% on a comparable basis supported by operating margin expansion of 120 basis points as reported and 100 basis points on a comparable basis
- Adjusts 2022 revenue guidance to 3.5% - 4.5% growth as reportedand 6.5% - 7.5% organic. At midpoint, reflects consistent reported revenue outlook as solid organic growth trends offset updated foreign exchange impacts
- Updated EPS outlook of $7.74 - $7.98 reflects consistent operational outlook at midpoint, supported by strong second half comparable operating profit gains, and incorporates $0.05 combined impact from updated foreign currency exchange rate and interest rate projections
WESTBROOK, Maine, Nov. 1, 2022 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results and an update on U.S. companion animal diagnostics trends.
Third Quarter Results
The Company reports revenues of $842 million for the third quarter of 2022, a 4% increase as reported and 8% organically, driven by Companion Animal Group ("CAG") Diagnostics recurring revenue growth of 5% reported and 9% organic, building on strong prior year performance. Results were supported by 10% reported and organic growth in U.S. CAG Diagnostics recurring revenues, reflecting continued benefits from strong IDEXX execution. Continued high companion animal sector demand and benefits from IDEXX innovation and commercial engagement drove record global premium instrument placements, which increased 10% compared to the prior year period. Veterinary software, services and diagnostic imaging systems revenue grew 14% as reported and 15% organically, supported by record quarterly placements of software solutions and a continued shift to cloud-based products. Overall revenue gains in the quarter were also supported by Water revenue growth of 7% reported and 12% organic.
Third quarter earnings per diluted share ("EPS") were $2.15, an increase of 6% as reported and 13% on a comparable basis, reflecting solid gross margin gains and controlled operating expense growth. EPS results included $0.08 per share negative impact from currency changes and no impact from tax benefits related to share-based compensation.
"Thanks to excellent execution by teams across the organization, IDEXX drove continued solid organic growth off elevated prior year levels in the third quarter," said Jay Mazelsky, President and Chief Executive Officer. "Record premium instrument placements in the quarter and gains across our business segments were supported by decades of innovation and strong customer engagement. By advancing our strategic priorities, IDEXX continues to help veterinarians deliver high standards of care in an efficient way as we pursue enduring growth aligned to the long-term global opportunity for companion animal diagnostics."
Companion Animal Diagnostics Trends Update
Continued elevated demand for companion animal healthcare supported solid gains in CAG diagnostic products and services. Average U.S. diagnostics revenue per practice grew 7% on a same-store basis in the third quarter, faster than 4% growth in overall clinic revenues. U.S. same-store clinical visits at veterinary practices declined 2.4%, a modest improvement compared to the prior quarter. Growth for pet healthcare including diagnostics has increased significantly from pre-pandemic levels reflecting compound annual growth of approximately 2.5% in clinical visits and 11% in same-store diagnostics revenues for the U.S. compared to the third quarter of 2019.
Additional U.S. companion animal practice key metrics are available in the Q3 2022 Earnings Snapshot accessible on the IDEXX website, www.idexx.com/investors.
Third Quarter Performance Highlights
Companion Animal Group
The Companion Animal Group generated revenue growth of 4% reported and 8% organic for the quarter, supported by CAG Diagnostics recurring revenue growth of 5% on a reported basis and 9% organically. Continued solid growth was achieved across IDEXX's testing modalities, building off high levels in the prior year period. Record premium instrument placements were 10% higher than the prior year period, driving a 14% year-over-year increase in the global premium instrument installed base.
- IDEXX VetLab® consumables generated 4% reported and 9% organic revenue growth, with solid organic gains across U.S. and international regions supported by benefits from an expanded global premium instrument installed base.
- Referencelaboratory diagnostic and consulting services generated 5% reported and 8% organic revenue growth, driven by strong gains in the U.S., which were moderated by modest organic revenue growth in international regions, reflecting pressure on same-store clinical visit growth in Europe — including macro-economic impacts.
- Rapid assay products revenues grew 5% as reported and 7% organically, supported by net price gains.
Veterinary software, services and diagnostic imaging systems revenues grew 14% as reported and 15% organically, supported by double-digit organic gains in recurring software and digital imaging revenues. Strong demand for cloud-based products continues to support momentum in software solution placements and customer gains.
Water
Water revenues grew 7% on a reported basis and 12% on an organic basis for the quarter, reflecting solid volume growth across U.S. and international regions and benefits from net price gains.
Livestock, Poultry and Dairy ("LPD")
LPD revenues declined 2% as reported and grew 7% on an organic basis for the quarter, benefiting from growth in herd health screening revenues and improved results in China.
Gross Profit and Operating Profit
Gross profits increased 7% as reported and 10% on a comparable basis. Gross margin of 60.2% increased 180 basis points as reported and 120 basis points on a comparable basis. Benefits from net price gains, lab productivity initiatives and improvement in software service gross margins offset select inflationary effects.
Operating margin was 29.1% in the quarter, 120 basis points higher than the prior year as reported and 100 basis points higher on a comparable basis, reflecting gross margin gains and controlled year-over-year operating expense growth of 6% as reported and 9% on a comparable basis. As planned, operating expense growth was in line with revenue gains as we prioritized investments and gained leverage from prior commercial investments.
2022 Growth and Financial Performance Outlook
The Company is updating its full-year revenue growth outlook to 3.5% - 4.5% as reported and 6.5% - 7.5% organically. The narrowed organic revenue growth range reflects solid third quarter performance and a fourth quarter outlook consistent with prior guidance. Updated foreign exchange projections will reduce reported revenue by $10 million, compared to the prior outlook, as a stronger U.S. dollar is now projected to reduce full-year reported growth by approximately 4%. The updated outlook includes full-year CAG Diagnostics recurring revenue growth of 4% - 5% as reported and 7.5% - 8.5% organically, supported by continued benefits from strong IDEXX execution including additional second half price gains.
The Company updated its full-year reported operating margin outlook to 26.3% - 26.8%, reflecting consistent expectations for operating margin performance on a comparable basis and an estimated ~ 10 basis points in year-over-year net margin impact from updated foreign currency exchange rate estimates.
The Company's EPS outlook of $7.74 - $7.98 reflects an adjustment of $0.05 at midpoint, including $0.01 of negative impact from higher projected interest rates and $0.04 of negative impact related to the strengthening U.S. dollar.
The following table provides the Company's updated outlook for annual key financial metrics in 2022:
| Amounts in millions except per share data and percentages | ||
|---|---|---|
| Growth and Financial Performance Outlook | 2022 | |
| Revenue | 3,325 | $3,365 |
| Reported growth | 3.5 % | 4.5 % |
| Organic growth | 6.5 % | 7.5 % |
| CAG Diagnostics Recurring Revenue Growth | ||
| Reported growth | 4 % | 5 % |
| Organic growth | 7.5 % | 8.5 % |
| Operating Margin | 26.3 % | 26.8 % |
| Operating margin expansion | (270 bps) | (220 bps) |
| Impact of foreign exchange | ~ 10 bps | |
| Comparable margin expansion | (280 bps) | (230 bps) |
| Impact of discrete in-license of technology | (230 bps) | |
| EPS | 7.74 | $7.98 |
| Reported growth | (10 %) | (7 %) |
| Comparable growth | (4 %) | (1 %) |
| Other Key Metrics | ||
| Net interest expense | ~ 39 | |
| Share-based compensation tax benefit | ~ 8 | |
| Share-based compensation tax rate benefit | ~ 1% | |
| Effective tax rate | 21.5 % | 22 % |
| Share-based compensation EPS impact | ~ 0.10 | |
| Reduction in average shares outstanding | ~ 2% | |
| Operating Cash Flow | 85% - 90% of net income | |
| Free Cash Flow | 60% - 65% of net income | |
| Capital Expenditures | ~ 165 |
All values are in US Dollars.
The following table outlines estimates of foreign currency exchange rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions reflected in the above financial performance outlook for 2022 and preliminary estimates for 2023.
| Go-Forward ForeignCurrency Exchange Rate Assumptions | 2022 |
|---|---|
| In U.S. dollars | |
| euro | 0.96 |
| British pound | 1.09 |
| Canadian dollar | 0.72 |
| Australian dollar | 0.62 |
| Relative to the U.S. dollar | |
| Japanese yen | 148 |
| Chinese renminbi | 7.26 |
| Brazilian real | R5.28 |
| Estimated Foreign Currency Exchange Rate Impacts | 2022 |
| Revenue growth rate impact | (~ 4%) |
| CAG Diagnostics recurring revenue growth rate impact | (~ 4%) |
| Operating margin growth impact | ~ 10 bps |
| EPS impact | (~ 0.25) |
| EPS growth impact | (~ 3%) |
All values are in US Dollars.
Conference Call and Webcast Information
IDEXX Laboratories, Inc. will be hosting a conference call today at 8:30 a.m. (EDT) to discuss its third quarter 2022 results and management's outlook. To participate in the conference call, dial 1-866-374-5140 or 1-404-400-0571 and reference pin 55765567. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the webcast will be available after 1:00 p.m. (EDT) on that day via the same link and will remain available for one year.
About IDEXX Laboratories, Inc.
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs more than 10,000 people and offers solutions and products to customers in more than 175 countries. For more information about IDEXX, visit www.idexx.com.
Note Regarding Forward-Looking Statements
This earnings release contains statements about the Company's business prospects and estimates of the Company's financial results for future periods that are forward-looking statements as defined in the PrivateSecurities Litigation Reform Act of 1995. Forward-looking statements are included above under "2022 Growth and Financial Performance Outlook" and elsewhere and can be identified by the use of words such as "expects", "may", "anticipates", "intends", "would", "will", "plans", "believes", "estimates", "projected", "should", and similar words and expressions. Our forward-looking statements include statements relating to our expectations regarding financial performance; revenue growth and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange rates and interest rates; projected operating margins and expenses and capital expenditures; projected tax, tax rate and EPS benefits from share-based compensation arrangements; and projected effective tax rates,reduction of average shares outstanding and net interest expense. These statements are intended to provide management's expectation of future events as of the date of this earnings release; are based on management's estimates, projections, beliefs and assumptions as of the date of this earnings release; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion and Analysis of Financial Condition and Results ofOperations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and in the corresponding sections of the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022, June 30, 2022, and September 30, 2022, as well as those described from time to time in the Company's other filings with the U.S. Securities and Exchange Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Statement Regarding Non-GAAP Financial Measures
The following defines terms and conventions and provides reconciliations regarding certain measures used in this earnings release and/or the accompanying earningsconference call that are not required by, or presented in accordance with, generally accepted accounting principles in the United States of America ("GAAP"), otherwise referred to as non-GAAP financial measures. To supplement the Company's consolidated results presented in accordance with GAAP, the Company has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors' evaluation of the Company's business performance and liquidity and are useful for period-over-period comparisons of the performance of the Company's business and its liquidity and to the performance and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating the Company's business, this information shouldbe considered as supplemental in nature and should not be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.
Constant currency - Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency exchange rates and are consistent with how management evaluates our performance and facilitates comparisons with prior and future periods. We estimated the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency hedging transactions and certain impacts on our effective tax rates. These estimated currency changes impacted third quarter 2022 results as follows: decreased gross profit growth by 3%, increased gross margin growth by 70 basis points, decreased operating expense growth by 3%, decreased operating profit growth by 4%, increased operating profit margin growth by 20 basis points, and decreased EPS growth by 4%. Constant currency revenue growth represents the percentage change in revenue during the applicable period, as compared to the prior year period, excluding the impact of changes in foreign currency exchange rates. See the supplementary analysis of results below for revenue percentage change from currency for the three months and nine months ended September 30, 2022 and refer to the 2022 Growth and Financial Performance Outlook section of this earnings release for estimated foreign currency exchange rate impacts on 2022 and 2023 projections and estimates.
Growth and organic revenue growth - All references to growth and organic growth refer to growth compared to the equivalent prior year period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that excludes the impact of changes in foreign currency exchange rates, certain business acquisitions, and divestitures. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier comparisons of our revenue performance with prior and future periods and to the performance of our peers. Organic revenue growth should be considered in addition to, and not as a replacement of or a superior measure to, revenue growth reported in accordance with GAAP. See the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three months and nine months ended September 30, 2022. Please refer to the 2022 Growth and Financial Performance Outlook section of this earnings release for estimated full-year 2022 organic revenue growth for the Company and CAG Diagnostics recurring revenue. The percentage change in revenue resulting from acquisitions represents revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that are directly attributable to business acquisitions. Revenue from acquisitions is expected to increase projected full-year 2022 revenue growth by 50 basis points and to have no impact to projected full-year 2022 CAG Diagnostics recurring revenue growth.
Comparable growth metrics - Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) are non-GAAP financial measures and exclude the impact of changes in foreign currency exchange rates and non-recurring or unusual items (if any). Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts. Management believes that reporting comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) provides useful information to investors because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding key metrics used by management. Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin gain (or growth) should be considered in addition to, and not as replacements of or superior measures to, gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain reported in accordance with GAAP.
The reconciliation of these non-GAAP financial measures is as follows:
| Three Months Ended | Year-over-Year | Nine Months Ended | Year-over-Year | |||
|---|---|---|---|---|---|---|
| September 30 | September 30 | Change | September 30 | September 30 | Change | |
| Dollar amounts in thousands | 2022 | 2021 | 2022 | 2021 | ||
| Gross Profit (as reported) | $ 506,626 | $ 472,921 | 7 % | $ 1,519,411 | $ 1,433,011 | 6 % |
| Gross margin | 60.2 % | 58.4 % | 180 bps | 59.8 % | 59.4 % | 50 bps |
| Less: comparability adjustments | ||||||
| Change from currency | (15,044) | — | (33,660) | — | ||
| Comparable gross profit growth | $ 521,670 | $ 472,921 | 10 % | $ 1,553,071 | $ 1,433,011 | 8 % |
| Comparable gross margin and gross margin gain (or growth) | 59.5 % | 58.4 % | 120 bps | 59.4 % | 59.4 % | — bps |
| Operating expenses (as reported) | $ 261,798 | $ 246,959 | 6 % | $ 847,173 | $ 700,174 | 21 % |
| Less: comparability adjustments | ||||||
| Change from currency | $ (6,887) | — | $ (15,272) | — | ||
| Comparable operating expense growth | $ 268,685 | $ 246,959 | 9 % | $ 862,445 | $ 700,174 | 23 % |
| Income from operations (as reported) | $ 244,828 | $ 225,962 | 8 % | $ 672,238 | $ 732,837 | (8) % |
| Operating margin | 29.1 % | 27.9 % | 120 bps | 26.5 % | 30.4 % | (390) bps |
| Less: comparability adjustments | ||||||
| Change from currency | (8,156) | — | (18,389) | — | ||
| Comparable operating profit growth | $ 252,984 | $ 225,962 | 12 % | $ 690,627 | $ 732,837 | (6) % |
| Comparable operating margin and operating margin gain (or growth) | 28.9 % | 27.9 % | 100 bps | 26.4 % | 30.4 % | (400) bps |
| Amounts presented may not recalculate due to rounding. |
Projected 2022 comparable operating margin expansion outlined in the 2022 Growth and Financial Performance Outlook section of this earnings release reflects projected full-year 2022 reported operating margin adjusted for estimated positive year-over-year foreign currency exchange rate change impact of approximately 10 basis points.
This impact and those described in the constant currency note above reconcile reported gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin gain (including projected 2022 operating margin expansion) to comparable gross profit growth, comparable gross margin gain, comparable operating expense growth, comparable operating profit growth and comparable operating margin gain for the Company.
Comparable EPS growth - Comparable EPS growth is a non-GAAP financial measure that represents the percentage change in earnings per share (diluted) ("EPS") for a measurement period, as compared to the prior base period, net of the impact of changes in foreign currency exchange rates from the prior base period and excluding the tax benefits of share-based compensation activity under ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, and non-recurring or unusual items (if any). Management believes comparable EPS growth is a more useful way to measure the Company's business performance than EPS growth because it enables better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding a key metric used by management. Comparable EPS growth should be considered in addition to, and not as a replacement of or a superior measure to, EPS growth reported in accordance with GAAP. Please refer to the constant currency note above for a summary of foreign currency exchange rate impacts.
The reconciliation of this non-GAAP financial measure is as follows:
| Three Months Ended | Year-over-Year | Nine Months Ended | Year-over-Year | |||
|---|---|---|---|---|---|---|
| September 30 | September 30 | Growth | September 30 | September 30 | Growth | |
| 2022 | 2021 | 2022 | 2021 | |||
| Earnings per share (diluted) | $ 2.15 | $ 2.03 | 6 % | $ 5.97 | $ 6.71 | (11) % |
| Less: comparability adjustments | ||||||
| Share-based compensation activity | 0.00 | 0.05 | 0.10 | 0.29 | ||
| Change from currency | (0.08) | — | (0.17) | — | ||
| Comparable EPS growth | 2.23 | 1.98 | 13 % | 6.04 | 6.42 | (6) % |
| Amounts presented may not recalculate due to rounding. |
Projected 2022 comparable EPS growth outlined in the 2022 Growth and Financial Performance Outlook section of this earnings release reflects adjustments including estimated positive share-based compensation activity of $0.10 and estimated negative year-over-year foreign currency exchange rate change impact of $0.25.
These impacts and those described in the constant currency note above reconcile reported EPS growth (including projected 2022 reported EPS growth) to comparable EPS growth for the Company.
Free cash flow - Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from operations during that period, reduced by the Company's investments in property and equipment. Management believes free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in property and equipment that are required to operate the business. Free cash flow should be considered in addition to, and not as a replacement of or a superior measure to, net cash provided by operating activities. See the supplementary analysis of results below for our calculation of free cash flow for the nine months ended September 30, 2022 and 2021. To estimate projected 2022 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of approximately $165 million. To calculate trailing twelve-month net income to free cash flow ratio for the twelve months ended September 30, 2022, we have deducted purchases of property and equipment of approximately $131 million from net cash provided from operating activities of approximately $580 million, divided by net income of approximately $670 million.
Debt to Adjusted EBITDA (Leverage Ratios) - Adjusted EBITDA, gross debt, and net debt are non-GAAP financial measures. Adjusted EBITDA is a non-GAAP financial measure of earnings before interest, taxes, depreciation, amortization, non-recurring transaction expenses incurred in connection with acquisitions, share-based compensation expense, and certain other non-cash losses and charges. Management believes that reporting Adjusted EBITDA, gross debt and net debt in the Debt to Adjusted EBITDA ratios provides supplemental analysis to help investors further evaluate the Company's business performance and available borrowing capacity under the Company's credit facility. Adjusted EBITDA, gross debt, and net debt should be considered in addition to, and not as replacements of or superior measures to, net income or total debt reported in accordance with GAAP. For further information on how Adjusted EBITDA and the Debt to Adjusted EBITDA Ratios are calculated, see the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.
| IDEXX Laboratories, Inc. and Subsidiaries | |||||
|---|---|---|---|---|---|
| Condensed Consolidated Statement of Operations | |||||
| Amounts in thousands except per share data (Unaudited) | |||||
| Three Months Ended | Nine Months Ended | ||||
| September 30, | September 30, | September 30, | September 30, | ||
| 2022 | 2021 | 2022 | 2021 | ||
| Revenue: | Revenue | $841,661 | $810,421 | $2,538,756 | $2,414,270 |
| Expenses andIncome: | Cost of revenue | 335,035 | 337,500 | 1,019,345 | 981,259 |
| Gross profit | 506,626 | 472,921 | 1,519,411 | 1,433,011 | |
| Sales and marketing | 130,021 | 124,434 | 392,570 | 358,277 | |
| General and administrative | 83,764 | 82,098 | 243,201 | 226,194 | |
| Research and development | 48,013 | 40,427 | 211,402 | 115,703 | |
| Income from operations | 244,828 | 225,962 | 672,238 | 732,837 | |
| Interest expense, net | (10,645) | (7,012) | (25,481) | (22,066) | |
| Income before provision for income taxes | 234,183 | 218,950 | 646,757 | 710,771 | |
| Provision for income taxes | 53,245 | 43,772 | 139,875 | 128,698 | |
| Net Income: | Net income | 180,938 | 175,178 | 506,882 | 582,073 |
| Less: Noncontrolling interest in subsidiary's earnings | — | (57) | — | (1) | |
| Net income attributable to stockholders | $180,938 | $175,235 | $506,882 | $582,074 | |
| Earnings per share: Basic | $2.17 | $2.06 | $6.04 | $6.82 | |
| Earnings per share: Diluted | $2.15 | $2.03 | $5.97 | $6.71 | |
| Shares outstanding: Basic | 83,247 | 85,123 | 83,855 | 85,325 | |
| Shares outstanding: Diluted | 84,113 | 86,511 | 84,858 | 86,712 | |
| IDEXX Laboratories, Inc. and Subsidiaries | |||||
| --- | --- | --- | --- | --- | --- |
| Selected Operating Information (Unaudited) | |||||
| Three Months Ended | Nine Months Ended | ||||
| September 30, | September 30, | September 30, | September 30, | ||
| 2022 | 2021 | 2022 | 2021 | ||
| OperatingRatios | Gross profit | 60.2 % | 58.4 % | 59.8 % | 59.4 % |
| (as a percentageof revenue): | Sales, marketing, general and administrative expense | 25.4 % | 25.5 % | 25.0 % | 24.2 % |
| Research and development expense | 5.7 % | 5.0 % | 8.3 % | 4.8 % | |
| Income from operations^1^ | 29.1 % | 27.9 % | 26.5 % | 30.4 % | |
| ^1^Amounts presented may not recalculate due to rounding. | |||||
| IDEXX Laboratories, Inc. and Subsidiaries | |||||
| --- | --- | --- | --- | ||
| Segment Information | |||||
| Amounts in thousands (Unaudited) | |||||
| Three Months Ended | |||||
| September 30,<br>2022 | September 30,<br>2021 | ||||
| Revenue: | CAG | 764,990 | 732,495 | ||
| Water | 40,840 | 38,143 | |||
| LPD | 28,452 | 29,126 | |||
| Other | 7,379 | 10,657 | |||
| Total | 841,661 | 810,421 | |||
| Gross Profit: | CAG | 456,334 | 423,871 | ||
| Water | 29,406 | 26,694 | |||
| LPD | 17,462 | 16,848 | |||
| Other | 3,424 | 5,508 | |||
| Total | 506,626 | 472,921 | |||
| Income fromOperations: | CAG | 221,454 | 201,947 | ||
| Water | 19,924 | 17,599 | |||
| LPD | 4,480 | 3,600 | |||
| Other | (1,030) | 2,816 | |||
| Total | 244,828 | 225,962 |
All values are in US Dollars.
| IDEXX Laboratories, Inc. and Subsidiaries | |||
|---|---|---|---|
| Segment Information | |||
| Amounts in thousands (Unaudited) | |||
| Nine Months Ended | |||
| September 30,<br>2022 | September 30,<br>2021 | ||
| Revenue: | CAG | 2,310,261 | 2,170,857 |
| Water | 116,406 | 109,374 | |
| LPD | 89,211 | 101,920 | |
| Other | 22,878 | 32,119 | |
| Total | 2,538,756 | 2,414,270 | |
| Gross Profit: | CAG | 1,371,687 | 1,277,531 |
| Water | 82,502 | 75,906 | |
| LPD | 54,005 | 63,255 | |
| Other | 11,217 | 16,319 | |
| Total | 1,519,411 | 1,433,011 | |
| Income fromOperations: | CAG | 601,105 | 649,892 |
| Water | 54,498 | 49,599 | |
| LPD | 14,447 | 24,276 | |
| Other | 2,188 | 9,070 | |
| Total | 672,238 | 732,837 |
All values are in US Dollars.
| IDEXX Laboratories, Inc. and Subsidiaries | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets | |||||||||
| Amounts in thousands (Unaudited) | |||||||||
| Three Months Ended | |||||||||
| September 30,2022 | September 30,2021 | DollarChange | ReportedRevenueGrowth^1^ | PercentageChange fromCurrency | PercentageChange fromAcquisitions | OrganicRevenueGrowth^1^ | |||
| Net Revenue | |||||||||
| CAG | $764,990 | $732,495 | $32,495 | 4.4 % | (4.1 %) | 0.1 % | 8.4 % | ||
| UnitedStates | 530,758 | 484,903 | 45,855 | 9.5 % | — | — | 9.4 % | ||
| International | 234,232 | 247,592 | (13,360) | (5.4 %) | (11.8 %) | 0.4 % | 6.0 % | ||
| Water | 40,840 | 38,143 | 2,697 | 7.1 % | (5.2 %) | 0.4 % | 11.8 % | ||
| UnitedStates | 20,940 | 19,216 | 1,724 | 9.0 % | — | — | 9.0 % | ||
| International | 19,900 | 18,927 | 973 | 5.1 % | (10.8 %) | 0.9 % | 15.0 % | ||
| LPD | 28,452 | 29,126 | (674) | (2.3 %) | (9.2 %) | — | 6.9 % | ||
| UnitedStates | 4,452 | 4,177 | 275 | 6.6 % | — | — | 6.6 % | ||
| International | 24,000 | 24,949 | (949) | (3.8 %) | (10.8 %) | — | 7.0 % | ||
| Other | 7,379 | 10,657 | (3,278) | (30.8 %) | (0.1 %) | — | (30.7 %) | ||
| TotalCompany | $841,661 | $810,421 | $31,240 | 3.9 % | (4.2 %) | 0.1 % | 7.9 % | ||
| UnitedStates | 560,292 | 514,343 | 45,949 | 8.9 % | — | — | 8.9 % | ||
| International | 281,369 | 296,078 | (14,709) | (5.0 %) | (11.4 %) | 0.4 % | 6.1 % | ||
| Three Months Ended | |||||||||
| September 30,2022 | September 30,2021 | DollarChange | ReportedRevenueGrowth^1^ | PercentageChange from<br><br>Currency | PercentageChange fromAcquisitions | OrganicRevenue<br><br>Growth^1^ | |||
| Net CAG Revenue | |||||||||
| CAG Diagnostics recurring revenue: | $667,309 | $638,358 | $28,951 | 4.5 % | (4.2 %) | 0.2 % | 8.6 % | ||
| IDEXX VetLab consumables | 262,820 | 252,714 | 10,106 | 4.0 % | (5.4 %) | — | 9.4 % | ||
| Rapid assay products | 80,542 | 76,974 | 3,568 | 4.6 % | (1.9 %) | — | 6.6 % | ||
| Reference laboratory diagnostic and consulting services | 295,590 | 282,301 | 13,289 | 4.7 % | (3.6 %) | 0.4 % | 8.0 % | ||
| CAG Diagnostics services and accessories | 28,357 | 26,369 | 1,988 | 7.5 % | (5.9 %) | — | 13.4 % | ||
| CAG Diagnostics capital – instruments | 35,176 | 39,401 | (4,225) | (10.7 %) | (5.5 %) | — | (5.2 %) | ||
| Veterinary software, services and diagnostic imaging systems | 62,505 | 54,736 | 7,769 | 14.2 % | (1.1 %) | — | 15.3 % | ||
| Net CAG revenue | $764,990 | $732,495 | $32,495 | 4.4 % | (4.1 %) | 0.1 % | 8.4 % | ||
| Three Months Ended | |||||||||
| September 30,2022 | September 30,2021 | DollarChange | ReportedRevenueGrowth^1^ | PercentageChange fromCurrency | PercentageChange from<br><br>Acquisitions | Organic<br><br>Revenue<br><br>Growth^1^ | |||
| CAG Diagnostics recurring revenue: | $667,309 | $638,358 | $28,951 | 4.5 % | (4.2 %) | 0.2 % | 8.6 % | ||
| United States | $459,077 | $418,728 | $40,349 | 9.6 % | — | — | 9.6 % | ||
| International | $208,232 | $219,630 | ($11,398) | (5.2 %) | (12.0 %) | 0.5 % | 6.3 % | ^1^See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding. | |
| --- | |||||||||
| IDEXX Laboratories, Inc. and Subsidiaries | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | ||
| Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets | |||||||||
| Amounts in thousands (Unaudited) | |||||||||
| Nine Months Ended | |||||||||
| September 30,2022 | September 30,2021 | DollarChange | ReportedRevenueGrowth^1^ | PercentageChange fromCurrency | PercentageChange fromAcquisitions | OrganicRevenueGrowth^1^ | |||
| Net Revenue | |||||||||
| CAG | $2,310,261 | $2,170,857 | $139,404 | 6.4 % | (3.1 %) | 0.9 % | 8.6 % | ||
| UnitedStates | 1,563,150 | 1,415,565 | 147,585 | 10.4 % | — | 1.2 % | 9.2 % | ||
| International | 747,111 | 755,292 | (8,181) | (1.1 %) | (8.8 %) | 0.4 % | 7.3 % | ||
| Water | 116,406 | 109,374 | 7,032 | 6.4 % | (3.5 %) | 0.1 % | 9.8 % | ||
| UnitedStates | 58,304 | 53,531 | 4,773 | 8.9 % | — | — | 8.9 % | ||
| International | 58,102 | 55,843 | 2,259 | 4.0 % | (6.9 %) | 0.3 % | 10.6 % | ||
| LPD | 89,211 | 101,920 | (12,709) | (12.5 %) | (5.2 %) | — | (7.3 %) | ||
| UnitedStates | 12,054 | 11,441 | 613 | 5.4 % | — | — | 5.4 % | ||
| International | 77,157 | 90,479 | (13,322) | (14.7 %) | (5.7 %) | — | (9.0 %) | ||
| Other | 22,878 | 32,119 | (9,241) | (28.8 %) | 0.5 % | — | (29.2 %) | ||
| TotalCompany | $2,538,756 | $2,414,270 | $124,486 | 5.2 % | (3.2 %) | 0.9 % | 7.5 % | ||
| UnitedStates | 1,646,023 | 1,502,219 | 143,804 | 9.6 % | — | 1.1 % | 8.5 % | ||
| International | 892,733 | 912,051 | (19,318) | (2.1 %) | (8.2 %) | 0.4 % | 5.7 % | ||
| Nine Months Ended | |||||||||
| September 30,2022 | September 30,2021 | DollarChange | Reported<br><br>RevenueGrowth^1^ | PercentageChange from<br><br>Currency | PercentageChange from<br><br>Acquisitions | Organic<br><br>Revenue<br><br>Growth^1^ | |||
| Net CAG Revenue | |||||||||
| CAG Diagnostics recurring revenue: | $2,017,532 | $1,916,938 | $100,594 | 5.2 % | (3.2 %) | 0.2 % | 8.2 % | ||
| IDEXX VetLab consumables | 796,072 | 755,158 | 40,914 | 5.4 % | (4.0 %) | — | 9.4 % | ||
| Rapid assay products | 242,542 | 230,472 | 12,070 | 5.2 % | (1.5 %) | — | 6.8 % | ||
| Reference laboratory diagnosticand consulting services | 894,795 | 851,757 | 43,038 | 5.1 % | (2.7 %) | 0.4 % | 7.3 % | ||
| CAG Diagnostics services and accessories | 84,123 | 79,551 | 4,572 | 5.7 % | (4.3 %) | — | 10.1 % | ||
| CAG Diagnostics capital – instruments | 108,400 | 105,645 | 2,755 | 2.6 % | (4.9 %) | — | 7.5 % | ||
| Veterinary software, services and<br><br>diagnostic imaging systems | 184,329 | 148,274 | 36,055 | 24.3 % | (0.9 %) | 11.0 % | 14.3 % | ||
| Net CAG revenue | $2,310,261 | $2,170,857 | $139,404 | 6.4 % | (3.1 %) | 0.9 % | 8.6 % | ||
| Nine Months Ended | |||||||||
| September 30,2022 | September 30,2021 | DollarChange | ReportedRevenue<br><br>Growth^1^ | Percentage<br><br>Change fromCurrency | PercentageChange fromAcquisitions | Organic<br><br>Revenue<br><br>Growth^1^ | |||
| CAG Diagnostics recurring revenue: | $2,017,532 | $1,916,938 | $100,594 | 5.2 % | (3.2 %) | 0.2 % | 8.2 % | ||
| United States | $1,351,936 | $1,239,213 | $112,723 | 9.1 % | — | 0.1 % | 9.0 % | ||
| International | $665,596 | $677,725 | ($12,129) | (1.8 %) | (8.8 %) | 0.5 % | 6.5 % | ^1^See Statements Regarding Non-GAAP Financial Measures, above. Amounts presented may not recalculate due to rounding. | |
| --- | |||||||||
| IDEXX Laboratories, Inc. and Subsidiaries | |||||||||
| --- | --- | --- | --- | ||||||
| Condensed Consolidated Balance Sheet | |||||||||
| Amounts in thousands (Unaudited) | |||||||||
| September 30, 2022 | December 31, 2021 | ||||||||
| Assets: | Current Assets: | ||||||||
| Cash and cash equivalents | $99,176 | $144,454 | |||||||
| Accounts receivable, net | 388,072 | 368,348 | |||||||
| Inventories | 354,975 | 269,030 | |||||||
| Other current assets | 216,636 | 173,823 | |||||||
| Total current assets | 1,058,859 | 955,655 | |||||||
| Property and equipment, net | 612,405 | 587,667 | |||||||
| Other long-term assets, net | 968,803 | 893,881 | |||||||
| Total assets | $2,640,067 | $2,437,203 | |||||||
| Liabilities and Stockholders' | |||||||||
| Equity: | Current Liabilities: | ||||||||
| Accounts payable | $110,144 | $116,140 | |||||||
| Accrued liabilities | 405,992 | 458,909 | |||||||
| Line of credit | 633,000 | 73,500 | |||||||
| Current portion of long-term debt | — | 74,996 | |||||||
| Deferred revenue | 40,809 | 40,034 | |||||||
| Total current liabilities | 1,189,945 | 763,579 | |||||||
| Long-term debt, net of current portion | 760,814 | 775,205 | |||||||
| Other long-term liabilities, net | 213,309 | 208,427 | |||||||
| Total long-term liabilities | 974,123 | 983,632 | |||||||
| Total stockholders' equity | 475,999 | 689,992 | |||||||
| Total liabilities and stockholders' equity | $2,640,067 | $2,437,203 | |||||||
| IDEXX Laboratories, Inc. and Subsidiaries | |||||||||
| --- | --- | --- | --- | --- | --- | --- | |||
| Select Balance Sheet Information (Unaudited) | |||||||||
| September 30,2022 | June 30,<br><br>2022 | March 31,2022 | December 31,<br><br>2021 | September 30,2021 | |||||
| Selected Balance Sheet Information: | Days sales outstanding^1^ | 43.4 | 43.2 | 42.0 | 42.4 | 42.7 | |||
| Inventory turns^2^ | 1.3 | 1.5 | 1.6 | 2.0 | 1.9 | ||||
| ^1^Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue for that quarter, the result of which is then multiplied by 91.25 days. | |||||||||
| --- | |||||||||
| ^2^Inventory turns represent inventory-related cost of product revenue for the twelve months preceding each quarter-end divided by the average inventory balances at the beginning and end of each quarter. | |||||||||
| IDEXX Laboratories, Inc. and Subsidiaries | |||||||||
| --- | --- | --- | --- | ||||||
| Condensed Consolidated Statement of Cash Flows | |||||||||
| Amounts in thousands (Unaudited) | |||||||||
| Nine Months Ended | |||||||||
| September 30, 2022 | September 30, 2021 | ||||||||
| Operating: | Cash Flows from Operating Activities: | ||||||||
| Net income | $506,882 | $582,073 | |||||||
| Non-cash adjustments to net income | 92,271 | 118,261 | |||||||
| Changes in assets and liabilities | (229,597) | (154,752) | |||||||
| Net cash provided by operating activities | 369,556 | 545,582 | |||||||
| Investing: | Cash Flows from Investing Activities: | ||||||||
| Purchases of property and equipment | (99,609) | (87,761) | |||||||
| Acquisition of intangible assets, businesses and equity investment | (46,512) | (161,166) | |||||||
| Net cash used by investing activities | (146,121) | (248,927) | |||||||
| Financing: | Cash Flows from Financing Activities: | ||||||||
| Borrowings under revolving credit facilities, net | 559,500 | — | |||||||
| Payment of senior debt | (75,000) | (50,000) | |||||||
| Payments for the acquisition-related contingent consideration and holdbacks | (5,730) | (1,500) | |||||||
| Repurchases of common stock | (745,691) | (502,021) | |||||||
| Proceeds from exercises of stock options and employee stock<br><br>purchase plans | 23,257 | 37,428 | |||||||
| Shares withheld for statutory tax withholding payments on<br><br>restricted stock | (10,552) | (15,501) | |||||||
| Net cash used by financing activities | (254,216) | (531,594) | |||||||
| Net effect of changes in exchange rates on cash | (14,497) | (3,786) | |||||||
| Net decrease in cash and cash equivalents | (45,278) | (238,725) | |||||||
| Cash and cash equivalents, beginning of period | 144,454 | 383,928 | |||||||
| Cash and cash equivalents, end of period | $99,176 | $145,203 | |||||||
| IDEXX Laboratories, Inc. and Subsidiaries | |||||||||
| --- | --- | --- | --- | ||||||
| Free Cash Flow | |||||||||
| Amounts in thousands except per share data (Unaudited) | |||||||||
| Nine Months Ended | |||||||||
| September 30, 2022 | September 30, 2021 | ||||||||
| Free Cash Flow: | Net cash provided by operating activities | $ 369,556 | $ 545,582 | ||||||
| Investing cash flows attributable to purchases of property and equipment | (99,609) | (87,761) | |||||||
| Free cash flow^1^ | $ 269,947 | $ 457,821 | |||||||
| ^1^See Statements Regarding Non-GAAP Financial Measures, above. | |||||||||
| IDEXX Laboratories, Inc. and Subsidiaries | |||||||||
| --- | --- | --- | --- | --- | |||||
| Common Stock Repurchases | |||||||||
| Amounts in thousands except per share data (Unaudited) | |||||||||
| Three Months Ended | Nine Months Ended | ||||||||
| September 30, 2022 | September 30, 2021 | September 30, 2022 | September 30, 2021 | ||||||
| Shares repurchased in the open market | 453 | 274 | 1,764 | 892 | |||||
| Shares acquired through employee surrender for statutory tax withholding | — | 1 | 21 | 29 | |||||
| Total shares repurchased | 453 | 275 | 1,785 | 921 | |||||
| Cost of shares repurchased in the open market | $ 166,423 | $ 183,315 | $ 742,661 | $ 510,937 | |||||
| Cost of shares for employee surrenders | 162 | 515 | 10,552 | 15,501 | |||||
| Total cost of shares | $ 166,585 | $ 183,830 | $ 753,213 | $ 526,438 | |||||
| Average cost per share – open market repurchases | $ 367.55 | $ 668.33 | $ 421.12 | $ 572.10 | |||||
| Average cost per share – employee surrenders | $ 387.07 | $ 688.35 | $ 502.26 | $ 547.90 | |||||
| Average cost per share – total | $ 367.56 | $ 668.38 | $ 422.07 | $ 571.36 |
CONTACT: John Ravis, Investor Relations, 1-207-556-8155
